Cell line · CVCL_0617
Papers55
1 to 20 of 55
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39464069 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. | Endocrinology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. | J Endocr Soc | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. | Mol Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. | Mol Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. | Cell Rep | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. | Cancers (Basel) | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. | Cell | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. | Cell Syst | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. | Cancer Res | 2018 | Cellosaurus cites it | PubMed | |
| Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. | Breast Cancer Res Treat | 2018 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0617/papers